Literature DB >> 11454661

Sirolimus, but not the structurally related RAD (everolimus), enhances the negative effects of cyclosporine on mitochondrial metabolism in the rat brain.

N Serkova1, W Jacobsen, C U Niemann, L Litt, L Z Benet, D Leibfritz, U Christians.   

Abstract

Clinical studies have shown enhancement of cyclosporine toxicity when co-administered with the immunosuppressant sirolimus. We evaluated the biochemical mechanisms underlying the sirolimus/cyclosporine interaction on rat brain metabolism using magnetic resonance spectroscopy (MRS) and compared the effects of sirolimus with those of the structurally related RAD. Two-week-old rats (25 g) were allocated to the following treatment groups (all n=6): I. control, II. cyclosporine (10 mg kg(-1) d(-1)), III. sirolimus (3 mg kg(-1) d(-1)), IV. RAD (3 mg kg(-1) d(-1)), V. cyclosporine+sirolimus and VI. cyclosporine+RAD. Drugs were administered by oral gavage for 6 days. Twelve hours after the last dose, metabolic changes were assessed in brain tissue extracts using multinuclear MRS. Cyclosporine significantly inhibited mitochondrial glucose metabolism (glutamate: 78+/-6% of control; GABA: 67+/-12%; NAD(+): 76+/-3%; P<0.05), but increased lactate production. Sirolimus and RAD inhibited cytosolic glucose metabolism via lactate production (sirolimus: 81+/-3% of control, RAD: 69+/-2%; P<0.02). Sirolimus enhanced cyclosporine-induced inhibition of mitochondrial glucose metabolism (glutamate: 60+/-4%; GABA: 59+/-8%; NAD(+): 45+/-5%; P<0.02 versus cyclosporine alone). Lactate production was significantly reduced. In contrast, RAD antagonized the effects of cyclosporine (glutamate, GABA, and NAD(+), not significantly different from controls). The results can partially be explained by pharmacokinetic interactions: co-administration increased the distribution of cyclosporine and sirolimus into brain tissue, while co-administration with RAD decreased cyclosporine brain tissue concentrations. In addition RAD, but not sirolimus, distributed into brain mitochondria. The combination of cyclosporine/RAD compares favourably to cyclosporine/sirolimus in regards to their effects on brain high-energy metabolism and tissue distribution in the rat.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11454661      PMCID: PMC1572850          DOI: 10.1038/sj.bjp.0704142

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  38 in total

Review 1.  Newer immunosuppressive drugs: a review.

Authors:  J F Gummert; T Ikonen; R E Morris
Journal:  J Am Soc Nephrol       Date:  1999-06       Impact factor: 10.121

2.  Tissue distribution and clinical monitoring of the novel macrolide immunosuppressant SDZ-RAD and its metabolites in monkey lung transplant recipients: interaction with cyclosporine.

Authors:  N Serkova; B Hausen; G J Berry; W Jacobsen; L Z Benet; R E Morris; U Christians
Journal:  J Pharmacol Exp Ther       Date:  2000-07       Impact factor: 4.030

Review 3.  Structure, function and regulation of pyruvate carboxylase.

Authors:  S Jitrapakdee; J C Wallace
Journal:  Biochem J       Date:  1999-05-15       Impact factor: 3.857

4.  Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats.

Authors:  A Crowe; A Bruelisauer; L Duerr; P Guntz; M Lemaire
Journal:  Drug Metab Dispos       Date:  1999-05       Impact factor: 3.922

5.  Combined immunosuppression with cyclosporine (neoral) and SDZ RAD in non-human primate lung transplantation: systematic pharmacokinetic-based trials to improve efficacy and tolerability.

Authors:  B Hausen; T Ikonen; N Briffa; G J Berry; U Christians; R C Robbins; L Hook; N Serkova; L Z Benet; W Schuler; R E Morris
Journal:  Transplantation       Date:  2000-01-15       Impact factor: 4.939

Review 6.  Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression.

Authors:  S N Sehgal
Journal:  Clin Biochem       Date:  1998-07       Impact factor: 3.281

Review 7.  Cyclosporine neurotoxicity: a review.

Authors:  J M Gijtenbeek; M J van den Bent; C J Vecht
Journal:  J Neurol       Date:  1999-05       Impact factor: 4.849

8.  Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group.

Authors:  B D Kahan
Journal:  Lancet       Date:  2000-07-15       Impact factor: 79.321

9.  In vitro and in situ absorption of SDZ-RAD using a human intestinal cell line (Caco-2) and a single pass perfusion model in rats: comparison with rapamycin.

Authors:  A Crowe; M Lemaire
Journal:  Pharm Res       Date:  1998-11       Impact factor: 4.200

10.  The novel immunosuppressant SDZ-RAD protects rat brain slices from cyclosporine-induced reduction of high-energy phosphates.

Authors:  N Serkova; L Litt; D Leibfritz; B Hausen; R E Morris; T L James; L Z Benet; U Christians
Journal:  Br J Pharmacol       Date:  2000-02       Impact factor: 8.739

View more
  22 in total

Review 1.  Exploiting immunometabolism and T cell function for solid organ transplantation.

Authors:  Jennifer B Allocco; Maria-Luisa Alegre
Journal:  Cell Immunol       Date:  2020-02-19       Impact factor: 4.868

2.  Immunophyllin ligands show differential effects on alcohol self-administration in C57BL mice.

Authors:  Thomas Beresford; Tina Fay; Natalie J Serkova; Peter H Wu
Journal:  J Pharmacol Exp Ther       Date:  2012-02-28       Impact factor: 4.030

3.  mTOR inhibitors and their role in modern concepts of immunosuppression.

Authors:  Björn Nashan
Journal:  World J Surg       Date:  2014-12       Impact factor: 3.352

4.  Low-salt diet and cyclosporine nephrotoxicity: changes in kidney cell metabolism.

Authors:  Jelena Klawitter; Jost Klawitter; Volker Schmitz; Nina Brunner; Amanda Crunk; Kyler Corby; Jamie Bendrick-Peart; Dieter Leibfritz; Charles L Edelstein; Joshua M Thurman; Uwe Christians
Journal:  J Proteome Res       Date:  2012-10-11       Impact factor: 4.466

Review 5.  Calcineurin signaling as a target for the treatment of alcohol abuse and neuroinflammatory disorders.

Authors:  Patrick J Ronan; Sarah A Flynn; Thomas P Beresford
Journal:  Prog Mol Biol Transl Sci       Date:  2019-08-12       Impact factor: 3.622

6.  Association of immunosuppressant-induced protein changes in the rat kidney with changes in urine metabolite patterns: a proteo-metabonomic study.

Authors:  Jost Klawitter; Jelena Klawitter; Erich Kushner; Karen Jonscher; Jamie Bendrick-Peart; Dieter Leibfritz; Uwe Christians; Volker Schmitz
Journal:  J Proteome Res       Date:  2010-02-05       Impact factor: 4.466

7.  Immunosuppressant neurotoxicity in rat brain models: oxidative stress and cellular metabolism.

Authors:  Jelena Klawitter; Sven Gottschalk; Carsten Hainz; Dieter Leibfritz; Uwe Christians; Natalie J Serkova
Journal:  Chem Res Toxicol       Date:  2010-03-15       Impact factor: 3.739

8.  Regulator of calcineurin 1 modulates expression of innate anxiety and anxiogenic responses to selective serotonin reuptake inhibitor treatment.

Authors:  Charles A Hoeffer; Helen Wong; Peter Cain; Josien Levenga; Kiriana K Cowansage; Yoon Choi; Camille Davy; Neil Majmundar; D Randy McMillan; Beverly A Rothermel; Eric Klann
Journal:  J Neurosci       Date:  2013-10-23       Impact factor: 6.167

Review 9.  Everolimus and sirolimus in transplantation-related but different.

Authors:  Jost Klawitter; Björn Nashan; Uwe Christians
Journal:  Expert Opin Drug Saf       Date:  2015-04-26       Impact factor: 4.250

10.  Alterations in glucose metabolism by cyclosporine in rat brain slices link to oxidative stress: interactions with mTOR inhibitors.

Authors:  Uwe Christians; Sven Gottschalk; Jelena Miljus; Carsten Hainz; Leslie Z Benet; Dieter Leibfritz; Natalie Serkova
Journal:  Br J Pharmacol       Date:  2004-08-31       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.